Light-Activated drug combo shows promise in fighting head and neck cancer
Disease control
Recruiting now
This study tests a new treatment called ASP-1929 photoimmunotherapy, which uses light to activate a drug that targets cancer cells, combined with the immunotherapy pembrolizumab. It is for people with head and neck cancer that has come back in the same area but has not spread to …
Phase: PHASE3 • Sponsor: Rakuten Medical, Inc. • Aim: Disease control
Last updated May 17, 2026 03:11 UTC